drugset / Trial / NCT01392794

A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet

NCT01392794

Phase 1 Completed 36 enrolled Astellas Pharma Inc
RandomizedCrossoverOpen-label

Summary

A study to compare time-course changes of plasma concentration of YM060 after intake of conventional tablet and orally-disintegrating tablet. Orally-disintegrating tablets will be administered without water.

Timeline

Start
2011-04
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramosetron Small molecule Oral

Indications

No indication recorded.